Product Description
Mechanisms of Action: IMPDH Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bausch Health Americas
Company Location: QUEBEC A8 H7L 4A8
Company CEO: Thomas J. Appio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Hepatitis A|Hepatitis C, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RNA003142-204 | P2 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2008-04-01 |